.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,234,906

« Back to Dashboard

Details for Patent: 5,234,906

Title: Hyperglycemic compositions
Abstract:Compositions having amylin or an amylin agonist and a glucagon compound, particularly peptide compounds, for the control of glucose production in mammals are provided. The compositions are useful in the treatment of hypoglycemia, including acute hypoglycemic conditions such as those brought on by insulin overdose and the overuse of oral hypoglycemic agents.
Inventor(s): Young; Andrew (San Diego, CA), Cooper; Garth J. S. (Solana Beach, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Jan 10, 1991
Application Number:07/640,478
Claims:1. A composition comprising glucagon and an amylin admixed in a form suitable for therapeutic administration.

2. A composition comprising a glucagon compound and an amylin agonist admixed in a form suitable for therapeutic administration.

3. The composition of claim 1 wherein said amylin is rat amylin.

4. The composition of claim 2 wherein said amylin agonist is a calcitonin gene-related peptide.

5. The composition of any of claims 1, 2 or 3 which is in lyophilized dosage unit form.

6. A method for enhancing glucose levels in a mammal, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4.

7. A method for the treatment of acute hypoglycemia in mammals, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4.

8. The method of claim 6 wherein said administration is by parenteral injection.

9. The method of claim 7 wherein said administration is by parenteral injection.

10. The method of claim 6 wherein said administration is by intravenous infusion.

11. The method of claim 7 wherein said administration is by intravenous infusion.

12. A method for the control of hypoglycemic conditions in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.

13. The method of claim 12 wherein said amylin agonist is amylin.

14. The method of claim 12 wherein said amylin agonist is a calcitonin gene-related peptide.

15. A method for the treatment of acute hypoglycemia in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.

16. The method of claim 15 wherein said amylin agonist is amylin.

17. The method of claim 15 wherein said amylin agonist is a calcitonin gene-related peptide.

18. The composition of claim 1 wherein said amylin is human amylin.

19. The composition of claim 2 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.

20. The composition of claim 2 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.

21. The method of claim 12 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.

22. The method of claim 15 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.

23. The method of claim 12 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.

24. The method of claim 15 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc